Xueba’s medical black technology system

Chapter 156 Request from the Food and Drug Administration

Lu Liang didn't speak, he just shook his head gently.

But Lu Liang's action stunned Xu Shoulin and others.

After a moment, Xu Shoulin seemed to understand something, and the expectation in his eyes slowly disappeared, replaced by disappointment.

Sure enough, the requirements are still too high?

Xu Shoulin couldn't help but sigh in his heart, and couldn't help but reveal a bitter smile on his lips.

But think about it, after all, the female doctor who developed sugalimab graduated from Johns Hopkins University with a doctorate, and she also specialized in oncology.

And Lu Liang is gone.

No matter how powerful Lu Liang is, he is still just an undergraduate at this stage.

Therefore, whether it is in terms of academic level or understanding of cancer, the two are completely different.

Isn't it just making things difficult for others by making such a request?

Xu Shoulin sighed, just as he was about to say thank you and leave.

Lu Liang spoke: "Actually, I am currently doing a batch of controlled trials, using sugemalimab as the drug control group, and then I found that the effect of sugemalimab is not as good as expected."

Lu Liang did not lie. He currently handed over the batch of experiments conducted by Wang Wentao.

It was to use sugalimab as the control and our own drug as the test group to compare the efficacy of the two drugs.

Judging from some of the data that have been released so far, our own drugs are still superior.

When hearing Lu Liang's words, everyone present, including Chen Shen, couldn't help but be stunned for two seconds.

At this moment, the entire conference room was silent.

Xu Shoulin and others looked at each other, especially Xu Shoulin, whose Adam's apple rolled.

"The effect of sugalimab is not as good as expected", here is what I mean.
But Xu Shoulin didn't dare to jump to conclusions, he was afraid that he would get another disappointing answer.

After a while, Xu Shoulin swallowed his saliva and asked tentatively: "Researcher Lu, what do you mean?"

"That's what it means."

Lu Liang spread his hands and said matter-of-factly: "From the data, my drug has a better therapeutic effect than sugalimab."

The moment Lu Liang finished speaking.

With a "swipe" sound, Xu Shoulin stood up almost subconsciously. Not only Xu Shoulin, but the other two people also opened their eyes wide.

"Bang!"

The sound of the water cup falling to the ground woke everyone up. Everyone turned around and found that it was Chen Shen who made the noise. Chen Shen looked shocked but excited at the same time.

He was so distracted for a short time that he couldn't hold the water glass in his hand.

After everyone came to their senses, they hurriedly found paper towels to wipe away the water stains on the floor.

After finally sorting things out in a hurry, everyone sat down again, but the shock that was difficult to conceal was still on their faces.

Especially Xu Shoulin.

He originally thought that if Lu Liang's drug could achieve similar efficacy to sugalimab, it would be quite remarkable.

He even felt that the idea of ​​expecting Lu Liang's drug to replace sugalimab was even a little bit delusional.

As for surpassing sugalimab, Xu Shoulin didn't dare to think about it.

Therefore, Lu Liang's answer made Xu Shoulin feel a little unreal for a while.

But after seeing everyone's reaction, Lu Liang couldn't help but frown.

To be honest, Xu Shoulin and others' reactions did not make him feel happy.Lu Liang even felt that he had been slightly insulted!
What an international joke.

Isn’t it a matter of course that my own medicine is better than sugalimab?

After all, no matter how powerful sugalimab is, it is nothing more than a PD-1 inhibitor.

The only immune checkpoint targeted is PD-1.

And its own drug is a PD-1/TIGIT inhibitor, which targets both PD-1 and TIGIT immune checkpoints.

In this case, if the therapeutic effect of my own drug on lung cancer is not as good as sugalimab.

I might as well just jump off the fourth floor.

What kind of research are you doing? You’re too embarrassed to see anyone.

Therefore, Lu Liang felt that his drug was compared with sugalimab, which was purely looking down on him.

Just as Lu Liang was thinking about these things, Lu Liang's cell phone rang with a message notification. Lu Liang picked up the phone and took a look.

I found out that the message was from Manager Nie.

Manager Nie: "Mr. Lu, some of the test results are out. The data are raw data. We haven't touched them. You can take a look first."

Immediately below is an excel table.

Lu Liang raised his eyebrows. It was a coincidence that the animal experiment data came out at this time.

Lu Liang opened the form and glanced at the data.

Judging from the data, the levels of indicators such as INF-γ and IL-4 in serum increased, while the levels of indicators such as carcinoembryonic antigen CEA and abnormal tumor protein decreased.

It is a pity that the pictures of pathological tissue morphology and section observation have not been released yet, otherwise it would be even more obvious.

However, the data has already come out, and the pictures are expected to be available soon.

Thinking of this, Lu Liang looked at Xu Shoulin and others and said, "My data has come out. Do you want to take a look?"

"no need."

Xu Shoulin waved his hand and replied with a smile: "However, since the results of the animal experiments on your side, Researcher Lu, have come out, when do you plan to start the Phase III clinical trial, Researcher Lu?"

Lu Liang thought for a moment and then replied: "I will start as soon as possible."

Xu Shoulin seemed to be relieved: "Okay, Researcher Lu, if you need our help, just ask."

"Thank you then."

After coming out of the Drug Research Institute, Xu Shoulin breathed a sigh of relief.

After solving the difficult problem, he also felt relaxed.

The woman who had been following Xu Shoulin couldn't help but smile on her face at this moment: "Director Xu, we finally solved this problem."

The other man couldn't help but nodded: "Yes, if it weren't for Researcher Lu, we would have had a headache for a while on how to deal with the Moco Company matter."

Until there is a suitable alternative to sugalimab, it will be difficult for them to deal with Moco.

After all, when drugs are removed from the shelves, lung cancer patients will definitely be implicated, but if the punishment is light, it will be painless to Moco, and the effect will be almost zero.

Xu Shoulin said: "So, we still have to thank Researcher Lu."

Then, the man on the side asked: "Director, do you want to prepare the punishment announcement for Moco Company now?"

Xu Shoulin thought for a moment and said, "No rush, let's wait until Researcher Lu's drug passes the Phase III clinical trial."

After all, the drug is still in Phase III clinical trials for some time, and during this period, patients still have to take the drug.

(End of this chapter)